Bavarian Biotech Report 2011/2012 (7MB) - Bio M

More documents

Recommendations

Info

Furthermore, the continued interest of Big Pharma intargeted “mini partnerships” in places such as theMunich metropolitan area – which we jointly implementwith companies and scientific institutions (resulting infirst concrete agreements) –demonstrates the top-classrelevance of technology and product development byBavarian researchers and companies on a global scale.Within this context, it is particularly important to constantlypromote and support the often cited “resource ofknowledge” that Germany essentially offers as a locationadvantage in the global competition. All of the abovementionedsuccesses by Bavarian biotechnology companiesarise from targeted support measures from thenational and the Bavarian state government at a particularBavarian location of higher education. In continuationof this successful science policy, Bavaria is currentlyfocusing strongly on systems biology (research networkfor molecular biosystems, BioSysNet), linking the excellentexpertise of the structural scientists working withProfessor Patrick Cramer at the Gene Centre of the LMUMunich with information technology and medical informaticsat other scientific locations in Bavaria in order topave the way for systems medicine. Furthermore, researchnetworks have also been established or are currentlybeing created or expanded across Bavaria in immunotherapyfor researching the metastasis of cancer andneurodegenerative disorders. This is also absolutelyessential for expanding the excellent scientific foundationat all locations.It is equally important to continuously improve thetechnology transfer of these findings in their application.We hope that the strengthening of translational researchin Bavarian clinical research departments will result inreal and possibly life-saving developments, especially forthe sake of the patients.There are frequently fundamental discussions in academiccircles about the orientation on application in research.One argument is that when researchers subjectthemselves to dependence upon business enterprisesand their changing needs, the “freedom” of sciencesuffers severely if the industrial partner makes the decisionas to whether or not the research findings arepublished. These discussions often fail to mention thatthis is not about hindering the acquisition of knowledgebut actually making it possible in the first place. In particular,the research landscape in the USA is an example ofhow private and/or corporate support is simply a prerequisitefor high-end research and its position (at the top)could never be adequately financed by public funds.The fact that these young entrepreneurs most recentlyalso come from life sciences is in part an achievement ofthe completely new “m 4 Award”. This award was conceivedin Munich’s Leading-Edge Cluster in order to grantfinancial support to academic projects in the proof-ofconceptphase. Thanks to generous support by the BavarianMinistry of Economic Affairs, this competition –which is now endowed with more than 8 million euros –was expanded across all of Bavaria and established inpartnership with all of the state’s facilities and networksthat are involved in technology transfer. This has closedthe gap that some inventors must face until they canparticipate with their idea in a business plan competitionand hopefully succeed in presenting themselves toinvestors. More than 80 project ideas were submittedafter the first call in 2011, and they have revealed thetypes of treasures slumbering at the research facilities inthe area of personalised medicine. It was then possibleto teach these scientists about approaching investors asthey received additional, targeted and professionalcoaching for example at a special „boot camp“.It is also important for such new entrepreneurs to find ahome for their company that allows it to grow. TheBavarian start-up centres play an essential – even indispensable– role in this respect: The IGZ in Wurzburgoffers office and laboratory space in an area of morethan 5,000 m 2 , which is currently used by more than 20companies with a total of 300 employees. The team ofthe IGZ also assists start-ups with business issuesranging from patenting to financing and gets activelyinvolved in measures to promote start-ups from theexceptionally well-positioned Department of Biomedicineat the University of Wurzburg and its hospital.The Medical Valley Centre in Erlangen focuses on medicaland diagnostic technology, as well as IT. It also offerscutting-edge equipment on 5,000 m 2 and an excellencenetwork of small and large global market leaders inmedical technology that received impressive awards inthe BMBF Leading-Edge Cluster competition.12
Straubing is fully committed to renewable resources.Open to all industries, the start-up centre is being complementedby a more specialised BioCubator – both ofwhich are in direct and ideal proximity to the CompetenceCentre for Renewable Resources of the TU München(Munich Technical University) in Straubing.The BioPark Regensburg has been set up on the campusof the University of Regensburg since 2001. It ceremoniouslyopened the third stage of construction in 2011and handed over the premises to the new tenants. As aresult, it now offers 18,000 m 2 of laboratory and officespace that is currently occupied by more than 30 tenantswith a total of more than 550 employees. A neighbouringproperty will provide more space for start-ups from allsectors in the near future, in addition to relocations toother commercial buildings in the Regensburg area. TheBioPark Regensburg GmbH not only serves as a facilitymanager but also as an industry development companyfor the entire Central Bavarian region – and has beenhighly successful in the process. Since life sciences aredeliberately defined very broadly here and expand intomedical technology, the area of Greater Regensburg witha population of 200,000 provides jobs in this sector for anotable number of 2,500 employees. Children and familiesare also offered benefits with the new children’sdaycare centre in the BioPark.LAB RESULTSYOU CAN TRUSTCUSTOMIZED CENTRAL LAB SERVICES WITHGLOBAL REACH FOR OUR SPONSORS’ SATISFACTIONSERVICES FOR BIOTECH COMPANIES· assay development and method validation· reliable sample transportation at any temp. range· biobanking: extended frozen storage· broad testing portfolio: e. g. biomarkers, geneticsGLOBAL STRENGTHS· one single global database· identical lab reports & flagging worldwide· global quality assurance / global SOPs· local support via dedicated project teamHead Office: Bayerstr. 53, 80335 Munich, GermanyPhone +49 89 7413930, info@interlab.de, www.interlab.de
Page 2 and 3: Our research benefits your health.T
Page 4 and 5: ImprintEditorial staff: Georg Kää
Page 6 and 7: Select IMGM as your outsourcing par
Page 8 and 9: The 2011 Biotech Year in Bavaria -A
Page 10 and 11: Due to this focus that was establis
Page 14 and 15: Last but not least, the IZB start-u
Page 16 and 17: Company FoundationsMerck-Sharp & Do
Page 18 and 19: Total number of employees in the Ba
Page 20 and 21: PHASE II4SC: Hepatocellular carcino
Page 22 and 23: Deals, Cooperation, Mergers, Financ
Page 24 and 25: M&A-ActivityIn early 2011 the acqui
Page 26: Due to the increasing number of new
Page 29: one so called “innovation allianc
Page 32 and 33: 4SC AGBIOTECH THERAPEUTICS & DIAGNO
Page 34 and 35: Contact:Dr. Luc St-OngeFraunhoferst
Page 36 and 37: Contact:Dr. Lars WassillWerkstr. 2D
Page 38 and 39: Apceth GmbH & Co. KGBIOTECH THERAPE
Page 40 and 41: Contact:Dr. Gundel HagerBahnhofstr.
Page 42 and 43: Bernina Plus GmbHBIOTECH THERAPEUTI
Page 44 and 45: Biontex Laboratories GmbHBIOTECH DE
Page 46 and 47: Carl Zeiss MicroImaging GmbHBIOTECH
Page 48 and 49: ChemDiv, Inc.CROContact:Dr. Anna Ni
Page 50 and 51: conoGenetix biosciences GmbHBIOTECH
Page 52 and 53: CoreLab Partners Europe GmbHCROCont
Page 54 and 55: Davids Biotechnologie GmbHBIOTECH D
Page 56 and 57: Dynamic BiosensorsBIOTECH DNA/PROTE
Page 58 and 59: Contact:Uschi LangGoethestr. 4D-803
Page 60 and 61: Eurofins MWG OperonBIOTECH DNA/PROT
Page 62 and 63:
FGK Clinical Research GmbHCROContac
Page 64 and 65:
GeneArt AGBIOTECHContact:Prof. Dr.
Page 66 and 67:
Contact:Dr. Korbinian GroteBayerstr
Page 68 and 69:
Contact:Peter Paul SchikoraMühlfel
Page 70 and 71:
Contact:Kurt MartinJosef-Engert-Str
Page 72 and 73:
ibidi GmbHBIOTECH DEVICES & REAGENT
Page 74 and 75:
Immumed GmbH -Gesellschaft für ang
Page 76 and 77:
INHECO GmbHBIOTECH DEVICES & REAGEN
Page 78 and 79:
IRIS Biotech GmbHPHARMA & CHEMICAL
Page 80 and 81:
KLIFOVET AGCROContact:Dr. Klaus Hel
Page 82 and 83:
LEUKOCARE AGBIOTECH DEVICES & REAGE
Page 84 and 85:
medicomp GmbHCROContact:Dr. med. ve
Page 86 and 87:
Contact:Dr. Erwin SoutschekFlorians
Page 88 and 89:
MLL Münchner Leukämie Labor GmbHB
Page 90 and 91:
multimmune GmbHBIOTECH THERAPEUTICS
Page 92 and 93:
NanoScape AGPHARMA & CHEMICAL INDUS
Page 94 and 95:
nexttec GmbHBIOTECH DNA/PROTEIN ANA
Page 96 and 97:
Contact:Michael AlmstetterAm Klopfe
Page 98 and 99:
PAN Biotech GmbHBIOTECH DEVICES & R
Page 100 and 101:
Pharma Stulln GmbHPHARMA & CHEMICAL
Page 102 and 103:
Phytochem Referenzsubstanzen GbRmbH
Page 104 and 105:
PreSens Precision Sensing GmbHBIOTE
Page 106 and 107:
Contact:Dr. Torsten NeuefeindBunsen
Page 108 and 109:
Ridom GmbHBIOTECH BIOINFORMATICSCon
Page 110 and 111:
SERVIER Deutschland GmbHPHARMA & CH
Page 112 and 113:
SSS International Clinical Research
Page 114 and 115:
TILL Photonics GmbHBIOTECH DEVICES
Page 116 and 117:
Tripos InternationalBIOTECH BIOINFO
Page 118 and 119:
vertis Biotechnologie AGBIOTECH DNA
Page 120 and 121:
Wilex AGBIOTECH THERAPEUTICS & DIAG
Page 124:
Where the future becomes realityHOT
show all

Bavarian Biotech Report 2011/2012 (7MB) - Bio M

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?